FDA Clears IND of VNX-101 in CD19+ Acute Lymphoblastic Leukemia
The FDA has cleared an investigational new drug (IND) application for VNX-101 for the treatment of CD19-positive acute lymphoblastic leukemia (ALL). VNX-101 is the first gene therapy product candidate from Vironexis Biotherapeutics. Enrollment of a phase 1 …